CSF3 and lymphoma: Likewise, patients diagnosed with lymphomas or other malignancies who received chemotherapy concurrently with G-CSF had similar lengths of hospital stay irrespective of receiving Neupogen® (median = 23.0, IQR = 21.0–27.5) or Grastofil® (median = 25.0, IQR = 23.0–29.0) (p = 0.24).